In the phase 2 FASCINATION trial, researchers sought to improve the rate of major molecular response 4 in patients newly diagnosed with CML.

Investigators evaluated outcomes for patients with pediatric AML with and without etoposide during first-line induction treatment.

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for TRN-257, a controlled-release, low-sodium oxybate product, for the treatment of cataplexy or excessive ...

Identity disclosure to a family member or friend linked to increased risks for suicide intention, plan, attempt.

The EPCORE FL-1 trial evaluated epcoritamb plus lenalidomide and rituximab versus plus lenalidomide and rituximab for efficacy and safety in patients with relapsed/refractory follicular lymphoma in ...

Patients with extensive-stage SCLC who received immunochemotherapy before 15:00 hrs exhibited significantly longer PFS, overall survival.

HealthDay News — A rare case of rabies linked to an organ transplant has resulted in 2 deaths, federal health officials announced. The US Centers for Disease Control and Prevention (CDC) reported that ...

In the phase 2 Smart Stop trial, researchers investigated the feasibility of achieving durable complete responses in DLBCL without the use of chemotherapy.

Omidubicel is a nicotinamide modified unrelated allogeneic hematopoietic progenitor cell therapy derived from cord blood.

Except for public health advocates (72% opposed), more than 60% of each speaker type supported approval. Patients and family members with drug experience had the highest support for approval (99%), 12 ...

At ASH 2025, researchers reported on 3-year efficacy and safety of lisocabtagene maraleucel in follicular lymphoma patients being treated in the third-line setting or later.

Incyte announced that a phase 3 program evaluating INCA033989 in ET patients with all types of CALR mutations is expected to begin in mid-2026.